Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Quality of Life and Rare Disease: Lessons from Spinal Muscular Atrophy
2 April 2019
The measurement of quality of life in the context of spinal muscular atrophy (SMA) is challenging. This is because the disease is experienced by children and…
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
20 March 2019
Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. A new OHE report provides empirical…
HTA in Japan: Failing to Meet International Good Practice?
15 March 2019
The Japanese government has recently announced new plans to implement HTA from April 2019. The ISPOR HTA Task Force published ‘Good Practices in HTA’ in January…
The World Needs Better Drugs for TB. The Center for Global Development and OHE Have a Proposal and We Need your Feedback
5 March 2019
Innovation is a critical tool in the global fight against tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the…
End of Life Treatments, Societal Values, and ‘Overall’ Preference
12 February 2019
OHE’s Koonal Shah gave a presentation on societal values and the provision of end of life treatments at a Manchester Centre for Health Economics seminar.
OHE Response to Public Consultation on NICE Principles
7 February 2019
OHE has submitted a response to the public consultation on updating the principles that guide the development of NICE guidance and standards.
Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
22 January 2019
Just published is a new OHE Consulting Report that explores society’s preferences across curative and non-curative therapies and large and small health gains.
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel,…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA,…